Progettazione e realizzazione di laboratori di quartiere nella periferia urbana di Padova con l’Architetto e Senatore Renzo Piano

Array ( [body] => Array ( [#theme] => field [#weight] => -4 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => foglia_complessa [#object] => stdClass Object ( [vid] => 503346 [uid] => 29556 [title] => Progettazione e realizzazione di laboratori di quartiere nella periferia urbana di Padova con l’Architetto e Senatore Renzo Piano [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121289 [type] => foglia_complessa [language] => it [created] => 1759387188 [changed] => 1759388116 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759388116 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_3] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

logo progetto LexTech Hub

Il progetto prevede la realizzazione di un laboratorio di quartiere in Viale Arcella a Padova, è stato sviluppato da ragazze e ragazzi che studiano o hanno studiato all’Università di Padova con la collaborazione dell’architetto Renzo Piano.

Il laboratorio sperimentale sarà il fulcro di nuove idee e prototipi per la città e i quartieri del futuro. Al momento il laboratorio è stato presentato alle autorità e alle realtà che in futuro collaboreranno con esso.

Il progetto è stato depositato in amministrazione comunale per ottenere le autorizzazioni per la sua realizzazione.

 

freccia rossaContatti


  • Riferimento del progetto: edoardo.narne@unipd.it
[summary] => [format] => 2 [safe_value] =>

logo progetto LexTech Hub

Il progetto prevede la realizzazione di un laboratorio di quartiere in Viale Arcella a Padova, è stato sviluppato da ragazze e ragazzi che studiano o hanno studiato all’Università di Padova con la collaborazione dell’architetto Renzo Piano.

Il laboratorio sperimentale sarà il fulcro di nuove idee e prototipi per la città e i quartieri del futuro. Al momento il laboratorio è stato presentato alle autorità e alle realtà che in futuro collaboreranno con esso.

Il progetto è stato depositato in amministrazione comunale per ottenere le autorizzazioni per la sua realizzazione.

 

freccia rossaContatti

[safe_summary] => ) ) ) [field_foglia_complessa_accordion] => Array ( ) [field_foglia_complessa_allegato] => Array ( ) [field_image_fc] => Array ( ) [field_testo_opzionale_fc] => Array ( ) [field_immagine_top] => Array ( ) [field_immagine_bottom] => Array ( ) [field_immagine_decorativa_latera] => Array ( ) [field_link_in_evidenza] => Array ( ) [field_usa_layout_pagina_link] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_etichetta_link_in_evidenza] => Array ( ) [field_tabs] => Array ( ) [field_condividi_social] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_formato_immagine] => Array ( ) [field_video_link] => Array ( ) [field_nosidebar] => Array ( [und] => Array ( [0] => Array ( [value] => 1 ) ) ) [field_chatbot] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_chatbot_codice_chat] => Array ( ) [field_header_custom] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_header_custom_ref] => Array ( ) [field_accessiway] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_footer_custom] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_footer_custom_ref] => Array ( ) [field_usa_layout_hero] => Array ( [und] => Array ( [0] => Array ( [value] => 0 ) ) ) [field_note_interne] => Array ( ) [field_url_en_page] => Array ( ) [field_crawler_ai] => Array ( ) [path] => Array ( [pathauto] => 0 ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 503346 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

logo progetto LexTech Hub

Il progetto prevede la realizzazione di un laboratorio di quartiere in Viale Arcella a Padova, è stato sviluppato da ragazze e ragazzi che studiano o hanno studiato all’Università di Padova con la collaborazione dell’architetto Renzo Piano.

Il laboratorio sperimentale sarà il fulcro di nuove idee e prototipi per la città e i quartieri del futuro. Al momento il laboratorio è stato presentato alle autorità e alle realtà che in futuro collaboreranno con esso.

Il progetto è stato depositato in amministrazione comunale per ottenere le autorizzazioni per la sua realizzazione.

 

freccia rossaContatti


  • Riferimento del progetto: edoardo.narne@unipd.it
[summary] => [format] => 2 [safe_value] =>

logo progetto LexTech Hub

Il progetto prevede la realizzazione di un laboratorio di quartiere in Viale Arcella a Padova, è stato sviluppato da ragazze e ragazzi che studiano o hanno studiato all’Università di Padova con la collaborazione dell’architetto Renzo Piano.

Il laboratorio sperimentale sarà il fulcro di nuove idee e prototipi per la città e i quartieri del futuro. Al momento il laboratorio è stato presentato alle autorità e alle realtà che in futuro collaboreranno con esso.

Il progetto è stato depositato in amministrazione comunale per ottenere le autorizzazioni per la sua realizzazione.

 

freccia rossaContatti

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

logo progetto LexTech Hub

Il progetto prevede la realizzazione di un laboratorio di quartiere in Viale Arcella a Padova, è stato sviluppato da ragazze e ragazzi che studiano o hanno studiato all’Università di Padova con la collaborazione dell’architetto Renzo Piano.

) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Progettazione e realizzazione di laboratori di quartiere nella periferia urbana di Padova con l’Architetto e Senatore Renzo Piano [href] => node/121289 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Progettazione e realizzazione di laboratori di quartiere nella periferia urbana di Padova con l’Architetto e Senatore Renzo Piano ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Elenco strutturato dei componenti aggiornato al 02.10.2025

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503338 [uid] => 26499 [title] => Elenco strutturato dei componenti aggiornato al 02.10.2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121288 [type] => allegato [language] => it [created] => 1759386619 [changed] => 1759386619 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386619 [revision_uid] => 26499 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Elenco strutturato dei componenti [format] => [safe_value] => Elenco strutturato dei componenti ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143036 [uid] => 26499 [filename] => Consulta_ElencoStrutturato_2025-10-01.pdf [uri] => public://2025/Consulta_ElencoStrutturato_2025-10-01.pdf [filemime] => application/pdf [filesize] => 115287 [status] => 1 [timestamp] => 1759386614 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503338 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Elenco strutturato dei componenti [format] => [safe_value] => Elenco strutturato dei componenti ) ) [#formatter] => text_default [0] => Array ( [#markup] => Elenco strutturato dei componenti ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503338 [uid] => 26499 [title] => Elenco strutturato dei componenti aggiornato al 02.10.2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121288 [type] => allegato [language] => it [created] => 1759386619 [changed] => 1759386619 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386619 [revision_uid] => 26499 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Elenco strutturato dei componenti [format] => [safe_value] => Elenco strutturato dei componenti ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143036 [uid] => 26499 [filename] => Consulta_ElencoStrutturato_2025-10-01.pdf [uri] => public://2025/Consulta_ElencoStrutturato_2025-10-01.pdf [filemime] => application/pdf [filesize] => 115287 [status] => 1 [timestamp] => 1759386614 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503338 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 143036 [uid] => 26499 [filename] => Consulta_ElencoStrutturato_2025-10-01.pdf [uri] => public://2025/Consulta_ElencoStrutturato_2025-10-01.pdf [filemime] => application/pdf [filesize] => 115287 [status] => 1 [timestamp] => 1759386614 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 143036 [uid] => 26499 [filename] => Consulta_ElencoStrutturato_2025-10-01.pdf [uri] => public://2025/Consulta_ElencoStrutturato_2025-10-01.pdf [filemime] => application/pdf [filesize] => 115287 [status] => 1 [timestamp] => 1759386614 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Elenco strutturato dei componenti aggiornato al 02.10.2025 [href] => node/121288 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Elenco strutturato dei componenti aggiornato al 02.10.2025 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Graduatorie terza chiamata - Erasmus 2025

Array ( [field_titolo_frontend] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503336 [uid] => 32 [title] => Graduatorie terza chiamata - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121287 [type] => elemento_accordion [language] => it [created] => 1759385935 [changed] => 1759385973 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759385973 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => aperto ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121286 [access] => 1 [node] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Graduatorie terza chiamata [format] => [safe_value] => Graduatorie terza chiamata ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503336 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Graduatorie terza chiamata [format] => [safe_value] => Graduatorie terza chiamata ) ) [#formatter] => text_default [0] => Array ( [#markup] => Graduatorie terza chiamata ) ) [field_allegato_element] => Array ( [#theme] => field [#weight] => -2 [#title] => Elemento allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_element [#field_type] => node_reference [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503336 [uid] => 32 [title] => Graduatorie terza chiamata - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121287 [type] => elemento_accordion [language] => it [created] => 1759385935 [changed] => 1759385973 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759385973 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => aperto ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121286 [access] => 1 [node] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Graduatorie terza chiamata [format] => [safe_value] => Graduatorie terza chiamata ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503336 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [nid] => 121286 [access] => 1 [node] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) [#formatter] => node_reference_default [0] => Array ( [#type] => link [#title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [#href] => node/121286 [#options] => Array ( [entity_type] => node [entity] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_accordion_state] => Array ( [#theme] => field [#weight] => -1 [#title] => Aperto/Chiuso [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_state [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503336 [uid] => 32 [title] => Graduatorie terza chiamata - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121287 [type] => elemento_accordion [language] => it [created] => 1759385935 [changed] => 1759385973 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759385973 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => aperto ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121286 [access] => 1 [node] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Graduatorie terza chiamata [format] => [safe_value] => Graduatorie terza chiamata ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503336 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => aperto ) ) [#formatter] => text_default [0] => Array ( [#markup] => aperto ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Graduatorie terza chiamata - Erasmus 2025 [href] => node/121287 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Graduatorie terza chiamata - Erasmus 2025 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_outline_level] => Array ( [#theme] => field [#weight] => 31 [#title] => Livello outline [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_outline_level [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503336 [uid] => 32 [title] => Graduatorie terza chiamata - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121287 [type] => elemento_accordion [language] => it [created] => 1759385935 [changed] => 1759385973 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759385973 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => aperto ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121286 [access] => 1 [node] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Graduatorie terza chiamata [format] => [safe_value] => Graduatorie terza chiamata ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503336 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => h3 ) ) [#formatter] => text_default [0] => Array ( [#markup] => h3 ) ) )

Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) [#formatter] => text_default [0] => Array ( [#markup] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503335 [uid] => 32 [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121286 [type] => allegato [language] => it [created] => 1759385929 [changed] => 1759386416 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759386416 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Medicina e chirurgia
Dipartimento di Scienze del farmaco (DSF) [format] => [safe_value] => Medicina e chirurgia<br>Dipartimento di Scienze del farmaco (DSF) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503335 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 143035 [uid] => 32 [filename] => Med_Farmacia.pdf [uri] => public://2025/Med_Farmacia.pdf [filemime] => application/pdf [filesize] => 117020 [status] => 1 [timestamp] => 1759385925 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 [href] => node/121286 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Medicina e chirurgia - Dipartimento di Scienze del farmaco (DSF) - Erasmus 2025 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

AI e selezione del personale - 30 ottobre 2025

Array ( [field_titolo_frontend] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503324 [uid] => 26499 [title] => AI e selezione del personale - 30 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121285 [type] => elemento_accordion [language] => it [created] => 1759333847 [changed] => 1759334578 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759334578 [revision_uid] => 26499 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[summary] => [format] => 2 [safe_value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => AI e selezione del personale - 30 ottobre 2025 [format] => [safe_value] => AI e selezione del personale - 30 ottobre 2025 ) ) ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503324 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => AI e selezione del personale - 30 ottobre 2025 [format] => [safe_value] => AI e selezione del personale - 30 ottobre 2025 ) ) [#formatter] => text_default [0] => Array ( [#markup] => AI e selezione del personale - 30 ottobre 2025 ) ) [body] => Array ( [#theme] => field [#weight] => -3 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503324 [uid] => 26499 [title] => AI e selezione del personale - 30 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121285 [type] => elemento_accordion [language] => it [created] => 1759333847 [changed] => 1759334578 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759334578 [revision_uid] => 26499 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[summary] => [format] => 2 [safe_value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => AI e selezione del personale - 30 ottobre 2025 [format] => [safe_value] => AI e selezione del personale - 30 ottobre 2025 ) ) ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503324 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[summary] => [format] => 2 [safe_value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

) ) [field_accordion_state] => Array ( [#theme] => field [#weight] => -1 [#title] => Aperto/Chiuso [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_state [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503324 [uid] => 26499 [title] => AI e selezione del personale - 30 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121285 [type] => elemento_accordion [language] => it [created] => 1759333847 [changed] => 1759334578 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759334578 [revision_uid] => 26499 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[summary] => [format] => 2 [safe_value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => AI e selezione del personale - 30 ottobre 2025 [format] => [safe_value] => AI e selezione del personale - 30 ottobre 2025 ) ) ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503324 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => chiuso ) ) [#formatter] => text_default [0] => Array ( [#markup] => chiuso ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about AI e selezione del personale - 30 ottobre 2025 [href] => node/121285 [html] => 1 [attributes] => Array ( [rel] => tag [title] => AI e selezione del personale - 30 ottobre 2025 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_outline_level] => Array ( [#theme] => field [#weight] => 31 [#title] => Livello outline [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_outline_level [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503324 [uid] => 26499 [title] => AI e selezione del personale - 30 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121285 [type] => elemento_accordion [language] => it [created] => 1759333847 [changed] => 1759334578 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759334578 [revision_uid] => 26499 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[summary] => [format] => 2 [safe_value] =>

L'incontro si focalizzerà sull'importanza di presentare al meglio la propria professionalità in un contesto in cui l'Intelligenza Artificiale gioca un ruolo sempre più determinante nei processi di selezione del personale.

Verranno analizzate le seguenti tematiche:

  • AI e il nuovo panorama della selezione del personale;
  • Creare un CV efficace e ottimizzato per ATS e AI
  • Scrivere prompt efficaci per la creazione di un CV efficace o per la preparazione a un colloquio
  • Introduzione a LinkedIn e scrittura di prompt efficaci per l'ottimizzazione del proprio profilo
  • Presentazione di tools con AI per il supporto alla creazione di CV e all'ottimizzazione del proprio profilo LinkedIn.

Relatori: Barbara Golinelli - University Talent Senior Consultant e Thomas Valmacco - University Talent Senior Consultant

L'incontro si tiene in presenza giovedì 30 ottobre dalle 11.30 alle 13 in aula 0D del complesso di Biologia Antonio Vallisneri, accessibile da Via Venezia, 1 (carrabile), Via Ugo Bassi, 587b (carrabile), Viale Giuseppe Colombo, 3 (pedonale).

Per partecipare è necessario iscriversi tramite la pagina di prenotazione.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => AI e selezione del personale - 30 ottobre 2025 [format] => [safe_value] => AI e selezione del personale - 30 ottobre 2025 ) ) ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503324 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => h3 ) ) [#formatter] => text_default [0] => Array ( [#markup] => h3 ) ) )

Presentazione aziendale Johnson & Johnson - 29 ottobre 2025

Array ( [field_titolo_frontend] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503308 [uid] => 32 [title] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121284 [type] => elemento_accordion [language] => it [created] => 1759326223 [changed] => 1759326223 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326223 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[summary] => [format] => 2 [safe_value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121283 [access] => 1 [node] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [format] => [safe_value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503308 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [format] => [safe_value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) [#formatter] => text_default [0] => Array ( [#markup] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) [body] => Array ( [#theme] => field [#weight] => -3 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503308 [uid] => 32 [title] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121284 [type] => elemento_accordion [language] => it [created] => 1759326223 [changed] => 1759326223 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326223 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[summary] => [format] => 2 [safe_value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121283 [access] => 1 [node] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [format] => [safe_value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503308 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[summary] => [format] => 2 [safe_value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

) ) [field_allegato_element] => Array ( [#theme] => field [#weight] => -2 [#title] => Elemento allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_element [#field_type] => node_reference [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503308 [uid] => 32 [title] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121284 [type] => elemento_accordion [language] => it [created] => 1759326223 [changed] => 1759326223 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326223 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[summary] => [format] => 2 [safe_value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121283 [access] => 1 [node] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [format] => [safe_value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503308 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [nid] => 121283 [access] => 1 [node] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) [#formatter] => node_reference_default [0] => Array ( [#type] => link [#title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [#href] => node/121283 [#options] => Array ( [entity_type] => node [entity] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_accordion_state] => Array ( [#theme] => field [#weight] => -1 [#title] => Aperto/Chiuso [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_state [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503308 [uid] => 32 [title] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121284 [type] => elemento_accordion [language] => it [created] => 1759326223 [changed] => 1759326223 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326223 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[summary] => [format] => 2 [safe_value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121283 [access] => 1 [node] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [format] => [safe_value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503308 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => chiuso ) ) [#formatter] => text_default [0] => Array ( [#markup] => chiuso ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [href] => node/121284 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_outline_level] => Array ( [#theme] => field [#weight] => 31 [#title] => Livello outline [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_outline_level [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 503308 [uid] => 32 [title] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121284 [type] => elemento_accordion [language] => it [created] => 1759326223 [changed] => 1759326223 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326223 [revision_uid] => 32 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[summary] => [format] => 2 [safe_value] =>

L’azienda è organizzata in due diversi settori di business: Farmaceutica e Dispositivi medici. J&J Innovative Medicine, la parte farmaceutica, è principalmente focalizzata su sei aree terapeutiche: immunologia, malattie infettive, neuroscienze, oncologia, cardiovascolare, metaboliche e polmonari. Il settore dei dispositivi e delle tecnologie medicali, J&J MedtTech, è impegnato da oltre un secolo nell’unire le più avanzate conoscenze scientifiche e tecnologiche per affrontare le pressanti sfide di chirurgia generale, ortopedia, cura della vista, cardiovascolare.

Johnson & Johnson si rivolge a persone iscritte all’ultimo anno, laureande e neolaureate dei corsi di laurea  triennale e magistrale nei seguenti ambiti di interesse: Ingegneria, Informatica, Biologia e Farmacia.

L’incontro si tiene presso l’Aula Magna Lepschy del Dipartimento di Ingegneria dell’Informazione (DEI) martedì 29 ottobre 2025 alle ore 10:00 e si struttura come segue:

  • Panoramica aziendale
  • Presentazione delle opportunità
  • Q&A

Per partecipare è necessario registrarsi e caricare il proprio CV entro lunedì 20 ottobre 2025.

[safe_summary] => ) ) ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 121283 [access] => 1 [node] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [format] => [safe_value] => Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503308 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => h3 ) ) [#formatter] => text_default [0] => Array ( [#markup] => h3 ) ) )

Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) [#formatter] => text_default [0] => Array ( [#markup] => Locandina ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503307 [uid] => 32 [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121283 [type] => allegato [language] => it [created] => 1759326201 [changed] => 1759326201 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759326201 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Locandina [format] => [safe_value] => Locandina ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 503307 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 143031 [uid] => 32 [filename] => Locandina Johnson & Johnson.pdf [uri] => public://2025/Locandina Johnson & Johnson.pdf [filemime] => application/pdf [filesize] => 354901 [status] => 1 [timestamp] => 1759326196 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 [href] => node/121283 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Locandina - Presentazione aziendale Johnson & Johnson - 29 ottobre 2025 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2025PV32 - Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025)

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503295 [uid] => 29556 [title] => 2025PV32 - Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121281 [type] => allegato [language] => it [created] => 1759320013 [changed] => 1759320013 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759320013 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) [format] => [safe_value] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143019 [uid] => 29556 [filename] => Lista vincitori - 2025PV32.pdf [uri] => public://2025/Lista vincitori - 2025PV32.pdf [filemime] => application/pdf [filesize] => 315030 [status] => 1 [timestamp] => 1759319774 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503295 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) [format] => [safe_value] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) ) ) [#formatter] => text_default [0] => Array ( [#markup] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 503295 [uid] => 29556 [title] => 2025PV32 - Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121281 [type] => allegato [language] => it [created] => 1759320013 [changed] => 1759320013 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759320013 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) [format] => [safe_value] => Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 143019 [uid] => 29556 [filename] => Lista vincitori - 2025PV32.pdf [uri] => public://2025/Lista vincitori - 2025PV32.pdf [filemime] => application/pdf [filesize] => 315030 [status] => 1 [timestamp] => 1759319774 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 503295 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 143019 [uid] => 29556 [filename] => Lista vincitori - 2025PV32.pdf [uri] => public://2025/Lista vincitori - 2025PV32.pdf [filemime] => application/pdf [filesize] => 315030 [status] => 1 [timestamp] => 1759319774 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 143019 [uid] => 29556 [filename] => Lista vincitori - 2025PV32.pdf [uri] => public://2025/Lista vincitori - 2025PV32.pdf [filemime] => application/pdf [filesize] => 315030 [status] => 1 [timestamp] => 1759319774 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2664 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2025PV32 - Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) [href] => node/121281 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2025PV32 - Lista dei vincitori/delle vincitrici (approvata con D.D.G. rep. n.3987/2025, prot. n. 208584 del 01.10.2025) ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Pink October: the AIRC foundation's campaign came back

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503306 [uid] => 26499 [title] => Pink October: the AIRC foundation's campaign came back [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121279 [type] => box_lancio_news [language] => it [created] => 1759319427 [changed] => 1759323942 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759323942 [revision_uid] => 13 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[summary] => [format] => 2 [safe_value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143008 [uid] => 26499 [filename] => n_cancroseno.jpg [uri] => public://n_cancroseno_1.jpg [filemime] => image/jpeg [filesize] => 24603 [status] => 1 [timestamp] => 1759313884 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 631 [width] => 1200 ) [height] => 631 [width] => 1200 [alt] => Photo of a healthcare worker with a pink ribbon pinned [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease [format] => [safe_value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa [format] => [safe_value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione in italiano [format] => [safe_value] => Versione in italiano ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 503306 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[summary] => [format] => 2 [safe_value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503306 [uid] => 26499 [title] => Pink October: the AIRC foundation's campaign came back [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121279 [type] => box_lancio_news [language] => it [created] => 1759319427 [changed] => 1759323942 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759323942 [revision_uid] => 13 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[summary] => [format] => 2 [safe_value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143008 [uid] => 26499 [filename] => n_cancroseno.jpg [uri] => public://n_cancroseno_1.jpg [filemime] => image/jpeg [filesize] => 24603 [status] => 1 [timestamp] => 1759313884 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 631 [width] => 1200 ) [height] => 631 [width] => 1200 [alt] => Photo of a healthcare worker with a pink ribbon pinned [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease [format] => [safe_value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa [format] => [safe_value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione in italiano [format] => [safe_value] => Versione in italiano ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 503306 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 143008 [uid] => 26499 [filename] => n_cancroseno.jpg [uri] => public://n_cancroseno_1.jpg [filemime] => image/jpeg [filesize] => 24603 [status] => 1 [timestamp] => 1759313884 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 631 [width] => 1200 ) [height] => 631 [width] => 1200 [alt] => Photo of a healthcare worker with a pink ribbon pinned [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 143008 [uid] => 26499 [filename] => n_cancroseno.jpg [uri] => public://n_cancroseno_1.jpg [filemime] => image/jpeg [filesize] => 24603 [status] => 1 [timestamp] => 1759313884 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 631 [width] => 1200 ) [height] => 631 [width] => 1200 [alt] => Photo of a healthcare worker with a pink ribbon pinned [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503306 [uid] => 26499 [title] => Pink October: the AIRC foundation's campaign came back [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121279 [type] => box_lancio_news [language] => it [created] => 1759319427 [changed] => 1759323942 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759323942 [revision_uid] => 13 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[summary] => [format] => 2 [safe_value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143008 [uid] => 26499 [filename] => n_cancroseno.jpg [uri] => public://n_cancroseno_1.jpg [filemime] => image/jpeg [filesize] => 24603 [status] => 1 [timestamp] => 1759313884 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 631 [width] => 1200 ) [height] => 631 [width] => 1200 [alt] => Photo of a healthcare worker with a pink ribbon pinned [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease [format] => [safe_value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa [format] => [safe_value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione in italiano [format] => [safe_value] => Versione in italiano ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 503306 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease [format] => [safe_value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease ) ) [#formatter] => text_default [0] => Array ( [#markup] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Pink October: the AIRC foundation's campaign came back [href] => node/121279 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Pink October: the AIRC foundation's campaign came back ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503306 [uid] => 26499 [title] => Pink October: the AIRC foundation's campaign came back [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121279 [type] => box_lancio_news [language] => it [created] => 1759319427 [changed] => 1759323942 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759323942 [revision_uid] => 13 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[summary] => [format] => 2 [safe_value] =>

In October 2025, the AIRC Foundation is launching the Pink Ribbon Campaign with the symbol of the incomplete ribbon, representing the yet-to-be-achieved goal of curing all forms of breast cancer, including the most aggressive ones. Thanks to advances in research, the five-year survival rate has risen to 88%, but every year in Italy there are still about 53,000 new diagnoses and one in eight women falls ill, while there remains a 12% of patients for whom there are still no effective therapies, particularly in cases of triple-negative and metastatic breast cancer affecting about 37,000 women.

To tackle these challenges, AIRC is investing 14 million euros in projects and scholarships in 2025, continuing a commitment that over 60 years has helped revolutionize breast cancer treatment, from trastuzumab to targeted therapies, to immunotherapy and immuno-conjugated antibodies.

As Anna Mondino, scientific director of the AIRC Foundation, explains, "Significant results have been achieved for the treatment of breast cancer: until almost thirty years ago, besides surgery, we could only resort to chemotherapy, radiotherapy, and hormonal therapies. Then in 1998, trastuzumab arrived, the first monoclonal antibody against a solid tumor. It is one of the drugs that has most revolutionized breast cancer treatment, particularly for HER2-positive cases, previously difficult to treat. Subsequently, researchers identified other molecular characteristics in specific groups of patients and types of cancer, developing targeted therapies capable of blocking the growth of cancer cells. Today, thanks to studies that took a few decades, we also have immunotherapy, a new frontier that is changing the history of this cancer when it is in the early stages. For advanced forms, immuno-conjugated antibodies can be used: drugs that have profoundly modified treatment protocols, offering significant survival benefits."

The campaign also emphasizes the importance of early diagnosis and prevention through healthy lifestyles, reminding that in Italy only 75% of women aged 50 to 69 undergo mammography, with significant differences between Northern and Southern Italy, and that factors such as physical inactivity, smoking, and alcohol consumption increase the risk of developing the disease.

To support research and raise awareness, people can wear the pin with the incomplete ribbon, distributed in pharmacies and participating stores, thanks to the "Together for Prevention" project and the support of numerous corporate and institutional partners, including The Estée Lauder Companies Italia as the main partner, along with organizations like Acqua Vitasnella, AICG, ALDI, ANCI, Cassa Centrale Banca, Chiquita, Coccinelle, Dr. Max, Magazzini Gabrielli, Marcolin, Veepee, and other distribution networks.

AIRC, which since 1965 has invested 2.5 billion euros supporting over 5,000 researchers in 96 Italian institutes and promoting a culture of prevention thanks to 4.5 million supporters and 20,000 volunteers, invites everyone to participate and get informed at airc.it.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143008 [uid] => 26499 [filename] => n_cancroseno.jpg [uri] => public://n_cancroseno_1.jpg [filemime] => image/jpeg [filesize] => 24603 [status] => 1 [timestamp] => 1759313884 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 631 [width] => 1200 ) [height] => 631 [width] => 1200 [alt] => Photo of a healthcare worker with a pink ribbon pinned [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease [format] => [safe_value] => In the month of international mobilization against breast cancer, the AIRC Foundation highlights the progress made over 60 years and supports research to combat even the most aggressive forms of the disease ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa [format] => [safe_value] => https://www.unipd.it/news/ottobre-rosa-riparte-campagna-nastro-rosa ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione in italiano [format] => [safe_value] => Versione in italiano ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 503306 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Rome [timezone_db] => Europe/Rome [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Mer, 01/10/2025 ) ) )

Project launched to save the Adriatic sturgeon from extinction

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503286 [uid] => 2032 [title] => Project launched to save the Adriatic sturgeon from extinction [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121278 [type] => box_lancio_news [language] => it [created] => 1759319197 [changed] => 1759319426 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759319426 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[summary] => [format] => 2 [safe_value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143017 [uid] => 2032 [filename] => Congiu con storione cobice.jpg [uri] => public://Congiu con storione cobice_0.jpg [filemime] => image/jpeg [filesize] => 138407 [status] => 1 [timestamp] => 1759319197 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 534 [width] => 1500 ) [height] => 534 [width] => 1500 [alt] => storione [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua [format] => [safe_value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione [format] => [safe_value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 503286 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[summary] => [format] => 2 [safe_value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503286 [uid] => 2032 [title] => Project launched to save the Adriatic sturgeon from extinction [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121278 [type] => box_lancio_news [language] => it [created] => 1759319197 [changed] => 1759319426 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759319426 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[summary] => [format] => 2 [safe_value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143017 [uid] => 2032 [filename] => Congiu con storione cobice.jpg [uri] => public://Congiu con storione cobice_0.jpg [filemime] => image/jpeg [filesize] => 138407 [status] => 1 [timestamp] => 1759319197 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 534 [width] => 1500 ) [height] => 534 [width] => 1500 [alt] => storione [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua [format] => [safe_value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione [format] => [safe_value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 503286 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 143017 [uid] => 2032 [filename] => Congiu con storione cobice.jpg [uri] => public://Congiu con storione cobice_0.jpg [filemime] => image/jpeg [filesize] => 138407 [status] => 1 [timestamp] => 1759319197 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 534 [width] => 1500 ) [height] => 534 [width] => 1500 [alt] => storione [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 143017 [uid] => 2032 [filename] => Congiu con storione cobice.jpg [uri] => public://Congiu con storione cobice_0.jpg [filemime] => image/jpeg [filesize] => 138407 [status] => 1 [timestamp] => 1759319197 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 534 [width] => 1500 ) [height] => 534 [width] => 1500 [alt] => storione [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503286 [uid] => 2032 [title] => Project launched to save the Adriatic sturgeon from extinction [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121278 [type] => box_lancio_news [language] => it [created] => 1759319197 [changed] => 1759319426 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759319426 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[summary] => [format] => 2 [safe_value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143017 [uid] => 2032 [filename] => Congiu con storione cobice.jpg [uri] => public://Congiu con storione cobice_0.jpg [filemime] => image/jpeg [filesize] => 138407 [status] => 1 [timestamp] => 1759319197 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 534 [width] => 1500 ) [height] => 534 [width] => 1500 [alt] => storione [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua [format] => [safe_value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione [format] => [safe_value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 503286 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua [format] => [safe_value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua ) ) [#formatter] => text_default [0] => Array ( [#markup] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Project launched to save the Adriatic sturgeon from extinction [href] => node/121278 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Project launched to save the Adriatic sturgeon from extinction ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 503286 [uid] => 2032 [title] => Project launched to save the Adriatic sturgeon from extinction [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 121278 [type] => box_lancio_news [language] => it [created] => 1759319197 [changed] => 1759319426 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1759319426 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[summary] => [format] => 2 [safe_value] =>

The European project LIFE-RESTORE – Recovery of Endangered Sturgeons Through Optimized Restocking Efforts has officially begun. It is dedicated to the protection of the Adriatic sturgeon (Acipenser naccarii), a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction.

Sturgeons today represent the most threatened group of fish species in the world: of the 26 existing species, all are considered at risk of extinction, mainly due to intensive fishing for caviar production and habitat loss. Among them, the Adriatic sturgeon holds particular importance: it is an Italian endemic species, found only in the Po River basin and the Adriatic Sea, and is classified as critically endangered.

Despite its extremely fragile condition, it is also the only sturgeon species worldwide that in recent years has shown weak but encouraging signs of recovery — a signal that makes the new project even more urgent and relevant.

The LIFE-RESTORE project, funded by the European Commission’s LIFE programme, aims to strengthen wild populations of Adriatic sturgeon. The project will last 72 months, with a total budget of over €10 million, and includes concrete actions for reproduction, breeding, reintroduction into the wild, and protection of river habitats. Advanced scientific monitoring, public engagement campaigns, and the development of coordinated long-term conservation strategies are also planned.

The main goals of LIFE-RESTORE are ambitious but concrete. The project intends to increase the number of Adriatic sturgeon by releasing more than 70,000 individuals into all rivers within their original range; reinforce the population through genetic-based selective breeding; reduce predation pressure from the invasive wels catfish, one of the most damaging alien species in our rivers; apply innovative monitoring techniques; and raise awareness about the sturgeon’s fundamental ecological role. In fact, the survival of this species is crucial for our waters, as the sturgeon is an “umbrella species,” meaning that its protection also benefits many other species sharing the same environment.

The partnership brings together universities, scientific institutes, natural parks, and associations, including the University of Padua (coordinator), the University of Ferrara, ISPRA, the Ticino Valley Regional Park, the Po Delta Regional Park, the Management Authority for the Protected Areas of the Piedmontese Po, the Delta Institute of Applied Ecology, GRAIA Ltd., Storione Ticino, and the Fish Heritage Protection Agency of Friuli-Venezia Giulia.

“Coordinating such a broad and highly qualified partnership is both a responsibility and a great honour,” says Leonardo Congiu, from the Department of Biology at the University of Padua and project coordinator. “With LIFE-RESTORE, we are bringing together scientific, institutional, and operational expertise to finally give the Adriatic sturgeon a real chance at survival. Working together, sharing goals and methods, is the only way to ensure concrete and lasting results.”

“LIFE-RESTORE is an innovative project because it puts into practice concrete conservation tools based on the most recent guidelines of the Pan-European Action Plan for sturgeons. It is a model of how scientific research and institutions can act in synergy to restore a symbolic species like the Adriatic sturgeon to a stable and lasting conservation status,” says Dr. Giovanna Marino (ISPRA – Research Director BIO-AMC and National Focal Point of the Pan-European Action Plan).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 143017 [uid] => 2032 [filename] => Congiu con storione cobice.jpg [uri] => public://Congiu con storione cobice_0.jpg [filemime] => image/jpeg [filesize] => 138407 [status] => 1 [timestamp] => 1759319197 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 534 [width] => 1500 ) [height] => 534 [width] => 1500 [alt] => storione [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua [format] => [safe_value] => The European project LIFE-RESTORE has been launched, dedicated to the protection of the Adriatic sturgeon, a symbolic species of our rivers and the Adriatic Sea, now at risk of extinction. The project involves universities, scientific institutes, natural parks, and associations, including the University of Padua ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [value2] => 2026-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione [format] => [safe_value] => /news/vi-ail-progetto-salvare-storione-cobice-dall-estinzione ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Italian version [format] => [safe_value] => Italian version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 503286 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2025-10-01T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Mer, 01/10/2025 ) ) )

Pagine